Alnylam Pharmaceuticals, Inc. (ALNY) on Decifer

Decifer ranks ALNY number 191 of 277 tracked names on durable business quality.

Why it ranks here

• It earns solid returns on the money it puts to work, around 14% and those returns have been improving and it turns most of its profit into real cash.
• Revenue is growing about 65% a year, profits grew 210% over the past year, and growth is speeding up, not slowing down.
• It keeps a high share of every sale as profit, and that has stayed steady over the years, a sign of real pricing power, with profitability widening as it grows.
• and has the balance sheet to fund its growth.
• We do not have a clean read on how it is run yet.
• Its profit margin and growth are both unusually high right now compared to its own history, the kind of combination that often fades once conditions normalize.
• Revenue growing 65% with profits up 210% is striking, but an unclear management read and momentum of 1 with the price below trend hold it back.

The current read

The evidence on ALNY lines up on the supportive side: the intelligence feed flags this name as connected to what is moving markets now. The independent signals we track are telling the same story.

Themes

• Next-Gen Genetic & RNA/Antibody Therapeutics: Platform breakthroughs in RNA interference, redosable gene therapy and antibody engineering are converting once-undruggable and orphan targets into commercial therapies.

Read the full ALNY research brief · See all quality rankings

Intelligence data powered by Decifer. Not financial advice. For informational purposes only.